Skip to main content

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 '22

By: Newsfile
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Dallas, Texas--(Newsfile Corp. - December 19, 2022) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners updates coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH). The full report can be accessed by clicking on the following link: https://stonegateinc.com/reports/BPTH_Q322.pdf

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Strong IP Position
  • Ongoing Clinical Trials
  • First Patients Recently Dosed

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/148698_figure1_550.jpg

Click image above to view full announcement.


About Stonegate Capital Partners
Stonegate Capital Partners is a Dallas-based corporate advisory firm dedicated to serving the specialized needs of small-cap public companies. Since our inception, our mission has been to find innovative, undervalued public companies for our network of leading institutional investors who seek high-quality investment opportunities.

Contacts:

Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/148698

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  258.51
-0.39 (-0.15%)
AAPL  319.97
-8.24 (-2.51%)
AMD  477.57
+21.41 (4.69%)
BAC  62.68
-0.04 (-0.06%)
GOOG  335.31
-3.77 (-1.11%)
META  616.77
+6.09 (1.00%)
MSFT  499.70
-10.42 (-2.04%)
NVDA  230.36
+1.91 (0.84%)
ORCL  158.78
+4.74 (3.08%)
TSLA  354.08
-22.29 (-5.92%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.